- conflicts or gaps
- [[{"field": {"value": "identity.founded_year", "source_urls": ["https://www.shasqi.com/about", "https://www.ycombinator.com/companies/shasqi"]}, "issue": {"value": "Company about page traces concept origin to 2014 when CEO left orthopedic residency; YC and CB Insights list company founded 2015.", "source_urls": ["https://www.shasqi.com/about", "https://www.ycombinator.com/companies/shasqi", "https://www.cbinsights.com/company/shasqi"]}}, {"field": {"value": "identity.former_names / yc_relationship", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2015/shasqi.json", "https://www.ycombinator.com/companies/shasqi"]}, "issue": {"value": "YC OSS lists former name Tambo; YC founder bio says Jose joined YC in 2015 with Tambo and in 2018 its spinoff Shasqi. Corporate continuity between Tambo and Shasqi not fully documented in primary filings checked.", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2015/shasqi.json", "https://www.ycombinator.com/companies/shasqi"]}}, {"field": {"value": "founders", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.shasqi.com/leadership"]}, "issue": {"value": "Only José M. Mejía Oneto is listed as founder across YC and company leadership pages; no co-founders named in primary sources checked.", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.shasqi.com/leadership"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://endpoints.news/a-better-way-to-control-where-drugs-go-investors-bet-on-small-biotechs-mission-to-click-together-cancer-meds/", "https://www.cbinsights.com/company/shasqi", "https://bouncewatch.com/company/shasqi"]}, "issue": {"value": "Total raised differs across sources: Endpoints $60M after Series B (Nov 2021); CB Insights $63.96M; BounceWatch $65.45M including additional NCI grants.", "source_urls": ["https://endpoints.news/a-better-way-to-control-where-drugs-go-investors-bet-on-small-biotechs-mission-to-click-together-cancer-meds/", "https://www.cbinsights.com/company/shasqi", "https://bouncewatch.com/company/shasqi"]}}, {"field": {"value": "funding.rounds[0].investors", "source_urls": ["https://www.shasqi.com/post/shasqi-completes-10-million-series-a-financing", "https://www.crunchbase.com/organization/endpoint-ventures", "https://www.cbinsights.com/company/shasqi/financials"]}, "issue": {"value": "Series A press release lists Y Combinator and high-net-worth private investors only; secondary databases also name Endpoint Ventures, Sage Venture Partners, and California Life Sciences Association.", "source_urls": ["https://www.shasqi.com/post/shasqi-completes-10-million-series-a-financing", "https://www.crunchbase.com/organization/endpoint-ventures", "https://www.cbinsights.com/company/shasqi/financials"]}}, {"field": {"value": "employees.snapshots", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://endpoints.news/a-better-way-to-control-where-drugs-go-investors-bet-on-small-biotechs-mission-to-click-together-cancer-meds/", "https://www.linkedin.com/company/shasqi-inc-"]}, "issue": {"value": "Headcount varies: YC team_size 28; Endpoints Nov 2021 reports 15-person team; LinkedIn lists 20 employees; BounceWatch lists 29.", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://yc-oss.github.io/api/batches/winter-2015/shasqi.json", "https://endpoints.news/a-better-way-to-control-where-drugs-go-investors-bet-on-small-biotechs-mission-to-click-together-cancer-meds/", "https://www.linkedin.com/company/shasqi-inc-", "https://bouncewatch.com/company/shasqi"]}}, {"field": {"value": "identity.headquarters_address", "source_urls": ["https://www.cbinsights.com/company/shasqi", "https://www.linkedin.com/company/shasqi-inc-"]}, "issue": {"value": "HQ suite numbers differ: CB Insights lists Suite 250 at 665 3rd Street; LinkedIn lists Suite 501 at 665 Third Street.", "source_urls": ["https://www.cbinsights.com/company/shasqi", "https://www.linkedin.com/company/shasqi-inc-"]}}, {"field": {"value": "identity.website", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2015/shasqi.json", "https://www.shasqi.com/"]}, "issue": {"value": "YC OSS API lists empty website field although company operates shasqi.com.", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2015/shasqi.json", "https://www.shasqi.com/"]}}, {"field": {"value": "products[1].clinical_status", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.centerwatch.com/clinical-trials/listings/NCT04106492/phase-1-2a-study-of-sq3370-in-patients-with-advanced-solid-tumors", "https://www.medrxiv.org/content/10.1101/2025.06.02.25328445v1"]}, "issue": {"value": "YC profile states lead asset in Phase 2; NCT04106492 is Overall Status Terminated after Phase 2a STS cohort did not meet prespecified efficacy continuation criteria vs standard doxorubicin.", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.centerwatch.com/clinical-trials/listings/NCT04106492/phase-1-2a-study-of-sq3370-in-patients-with-advanced-solid-tumors", "https://www.medrxiv.org/content/10.1101/2025.06.02.25328445v1"]}}, {"field": {"value": "funding.yc_investment_amount_usd", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.linkedin.com/company/shasqi-inc-"]}, "issue": {"value": "No primary-source YC investment dollar amount found; LinkedIn secondary data lists $120K pre-seed in 2015 not confirmed by company or YC.", "source_urls": ["https://www.ycombinator.com/companies/shasqi", "https://www.linkedin.com/company/shasqi-inc-"]}}, {"field": {"value": "products.pipeline", "source_urls": ["https://www.shasqi.com/pipeline"]}, "issue": {"value": "Public pipeline page does not name specific follow-on drug candidates beyond SQ3370/SQL70/SQP22 references in other materials.", "source_urls": ["https://www.shasqi.com/pipeline", "https://www.drugdiscoverytrends.com/click-chemistry-shasqi-jj-partnership/"]}}]]
- source urls
- ["https://bouncewatch.com/company/shasqi", "https://endpoints.news/a-better-way-to-control-where-drugs-go-investors-bet-on-small-biotechs-mission-to-click-together-cancer-meds/", "https://www.biospace.com/shasqi-awarded-a-second-nci-grant-of-1-9m-to-accelerate-the-development-of-sq3370", "https://www.businesswire.com/news/home/20211111005433/en/Shasqi-Raises-50-Million-to-Expand-Click-Chemistry-Platform-Beyond-Injectable-Tumors-and-Accelerate-Lead-Clinical-Program", "https://www.cbinsights.com/company/shasqi", "https://www.cbinsights.com/company/shasqi/financials", "https://www.centerwatch.com/clinical-trials/listings/NCT04106492/phase-1-2a-study-of-sq3370-in-patients-with-advanced-solid-tumors", "https://www.crunchbase.com/organization/endpoint-ventures", "https://www.drugdiscoverytrends.com/click-chemistry-shasqi-jj-partnership/", "https://www.linkedin.com/company/shasqi-inc-", "https://www.medrxiv.org/content/10.1101/2025.06.02.25328445v1", "https://www.shasqi.com/", "https://www.shasqi.com/about", "https://www.shasqi.com/leadership", "https://www.shasqi.com/pipeline", "https://www.shasqi.com/post/phase-2a-results-of-sq3370-a-doxorubicin-based-click-chemistry-therapeutic-in-advanced-sts-patients-planned-interim-analysis", "https://www.shasqi.com/post/shasqi-announces-research-collaboration-to-transform-targeted-cancer-treatment", "https://www.shasqi.com/post/shasqi-completes-10-million-series-a-financing", "https://www.shasqi.com/post/shasqi-raises-50-million-to-expand-click-chemistry-platform-beyond-injectable-tumors-and-accelerate-lead-clinical-program", "https://www.shasqi.com/post/shasqi-strengthens-board-of-directors-with-the-appointment-of-former-chief-development-officer-at-pfizer-oncology", "https://www.ycombinator.com/companies/shasqi", "https://yc-oss.github.io/api/batches/winter-2015/shasqi.json"]